Broadly covered and affordable for most patients*

Because LEQVIO^® is administered by an HCP, it is covered primarily under the medical benefit, not the pharmacy benefit

For traditional Medicare patients, LEQVIO may be:

Covered, Affordable

No prior authorization required

---

Have supplemental plans and
may pay as little as $0

Some supplemental plans may require
precertification or prior authorization.

---

Part B medical benefit

---

Not subject to the Part D
pharmacy benefit donut hole

For commercial & Medicare patients, LEQVIO may be:

Covered

Have confirmed coverage on
the medical benefit for LEQVIO

---

Patients' medical insurance plans
do not require a step through another injectable

---

Higher approval rates when
appropriately submitted under
the medical benefit

---

Affordable

May pay as little as $0

---

Patients pay

Out-of-pocket annually vs other branded nonstatin treatments, including PCSK9 mAbs^†

For Medicaid patients, LEQVIO may be:

Affordable

Patients pay less than

PCSK9 mAb, proprotein convertase subtilisin/kexin type 9 monoclonal antibody.

*Coverage information is subject to change by the relevant plan and is based on data up to July 2023. The information provided in this communication is not a guarantee of coverage or payment (partial or full). Actual coverage and reimbursement decisions are made by individual payers following the receipt of claims.

^†The comparison pertains only to differences in cost and should not be considered a comparison of efficacy or safety.